Skip to main content
Moderna, Inc. logo

Moderna, Inc. — Investor Relations & Filings

Ticker · MRNA ISIN · US60770K1079 LEI · 549300EI6OKH5K5Q2G38 US Manufacturing
Open in API
Filings indexed 1,448 across all filing types
Latest filing 2021-01-04 Regulatory Filings
Country US United States of America
Listing US MRNA

About Moderna, Inc.

https://www.modernatx.com/

Moderna, Inc. is a biotechnology company pioneering the development of messenger RNA (mRNA) therapeutics and vaccines. The company's core platform utilizes mRNA to carry instructions that direct the body's cells to produce proteins, thereby preventing or treating diseases. This technology enables the rapid design, research, and production of new medicines. Moderna is widely recognized for developing one of the first COVID-19 vaccines. Its research and development pipeline extends to various therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders. The company's mission is to create a new generation of transformative medicines for patients by leveraging the potential of its mRNA platform.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that Moderna issued a letter to shareholders regarding its cash, cash equivalents, and investments as of December 31, 2020, attached as Exhibit 99.1. The document does not contain detailed financial statements or comprehensive financial analysis but rather a letter with expectations and disclosures. The length is 3738 characters, which is relatively short and consistent with a current report rather than a full financial report. The Form 8-K is typically used for regulatory announcements and disclosures rather than full reports like Annual or Interim Reports. Therefore, this filing fits best under Regulatory Filings (RNS), as it is a regulatory announcement of a letter to shareholders and not a full financial report or earnings release.
2021-01-04 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-31 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-31 English
4 Filing
Director's Dealing
2020-12-29 English
4 Filing
Director's Dealing
2020-12-29 English
4 Filing
Director's Dealing
2020-12-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.